
Jul 23, 2026
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Cosmo N.V. has reported significant growth in recurring revenues for the first half of 2026, driven by strong performances from its key products and advancements in its clinical pipeline.The company achieved a notable 38% increase in revenue from Winlevi® and a 35% rise from Lialda®, alongside a 14% growth in its Contract Development and Manufacturing Organization (CDMO) segment. This growth underscores the strength and diversification of Cosmo's business model. Furthermore, the Phase III clinic









